Briacell Therap (NASDAQ:BCTX) Sees Significant Decrease in Short Interest

Briacell Therap (NASDAQ:BCTX) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 377,009 shares, a drop of 56.6% from the May 31st total of 867,761 shares. Approximately 4.4% of the company’s stock are short sold. Based on an average daily volume of 250,931 shares, the short-interest ratio is currently 1.5 days.

Briacell Therap Stock Up 1.3%

NASDAQ BCTX opened at $3.10 on Monday. Briacell Therap has a 52 week low of $2.60 and a 52 week high of $31.10. The company has a 50 day moving average price of $3.53 and a 200 day moving average price of $4.75. The firm has a market cap of $26.98 million, a PE ratio of -0.39 and a beta of 1.21.

Briacell Therap (NASDAQ:BCTX) last announced its earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share for the quarter.

Wall Street Analyst Weigh In

BCTX has been the topic of several recent research reports. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC bought a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned approximately 0.21% of Briacell Therap at the end of the most recent reporting period. Institutional investors own 15.42% of the company’s stock.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.